All In Biotech

Drug Trial Radar · NCT06736327

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Jul 31, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SKB500Drug

    The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the incidence of adverse events (AEs)Time frame: Up to 3 years
  2. Evaluate the incidence of serious adverse events (SAEs)Time frame: Up to 3 years
  3. Evaluate the incidence of treatment related adverse events (TRAEs)Time frame: Up to 3 years
  4. Evaluate the incidence of dose-limiting toxicities (DLTs)Time frame: Day 1 to Day 21 in Cycle 1 in the dose escalation part

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JILIN Cancer Hospital

    Jilin City, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.